STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more
Approximately two in five GLP-1 users modified their use of the medication from the way it was prescribed, often citing cost and availability as barriers to prescribed use.
- adults reported taking a GLP-1 medication during the previous year, according to a report from the Centers for Disease Control and Prevention.
- The International Federation of Pharmaceutical Manufacturers is pushing for one of the so-called Big 4 accounting firms to audit industry contributions to the WHO’s Pandemic IInfluenza Preparedness Framework, citing concerns over how the funds are used.
- We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings, and phone calls has predictably returned.
Among GLP-1 users, approximately one in five reported taking a compounded version and 9% of those taking a GLP-1 medicine were uncertain whether it was compounded, suggesting difficulties in distinguishing compounded versions from medicines approved by the U.S.
- Continue to STAT+ to read the full story….
- Meanwhile, here are a few items of interest to start you on your journey, which we hope is meaningful and productive.
- However, the WHO says it already has an external auditor and that it spends all funds in accordance with its rules.
- So time to give it a nudge in a better direction by brewing cups of stimulation.
- Good morning, everyone, and welcome to another working week.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →